October 23, 2013
New York, New York
Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the merger of Washington Banking Company on behalf of its shareholders. Under the terms of the merger agreement, Washington Banking shareholders will receive 0.89000 shares of Heritage common stock and $2.75 in cash for each share of Washington Banking common stock. Based on the closing price of Heritage common stock of $15.89 on October 23, 2013, the consideration value per share for Washington Banking was $16.89, or approximately $265.1 million in aggregate. Upon consummation, the shareholders of Washington Banking will own approximately 46% of the combined company and the shareholders of Heritage will own approximately 54%.
The investigation concerns whether the Board of Directors of Washington breached their fiduciary duties by not engaging in a full and fair process to insure that shareholders receive the maximum value for their shares. Indeed, analysts have projected that the inherent value of Washington is greater than that of the merger consideration. If you are a shareholder of Washington and would like additional information regarding this matter at no cost please contact us toll free at 1-877-772-3975 or email at contact @ tripplevy. Tripp Levy is a national law firm with extensive experience in mergers and has recovered millions for shareholders around the globe.
Attorney advertising, prior results do not indicate future matters
Thanks for this...i called and you had to have purchased your shares since Dec. 2010 (and have losses). There is no cost to joining. All please no haters in posting how bad the lawyers are. There is no other recourse for shareholders to get their money back so at least someone is willing to do something...so please no hate mail on this post
what's with the bashing...what other options are there...do nothing and you get back anything...i rather get something back then nothing...count me in.
this is an entirely different kind of action....here they are required to give plaintiffs any recoveries and only if they get benefits for shareholders do they make an application to the court to award them fees. Its apples and oranges and here where everyone has lost their shirts this is the only way to get a recovery...what else you gonna do..no other option.
fyi....the proxy was just filed...shareholders only have days left before this deal closes and shareholders are forced to get the lowball offer...here is number of law firm in case anyone else wants to join up and try and get a higher price (there is no cost in joining)...1 -877-772-3975
Tripp Levy PLLC announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of purchasers of Atossa Genetics, Inc. ("Atossa" or the "Company") (ATOS) securities during the period between November 8, 2012 and October 4, 2013, inclusive (the "Class Period").
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that the Company was required, but failed, to submit documentation necessary to obtain clearance from the U.S. Food and Drug Administration ("FDA") after making changes to its Nipple Aspirate Fluid specimen collection process, that the Company improperly marketed its ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test ("MASCT"), and that the Company violated the FDA's Good Manufacturing Practices regulations. According to the complaint, following the Company's February 25, 2013 disclosure that it had received a warning letter from the FDA regarding the Company's failure to submit required documentation required due to changes to its MASCT System and MASCT System Collection Test (together, the "System") and which raised issues with respect to the marketing of the System and the Company's compliance with FDA Good Manufacturing Practices regulations, and following the Company's October 4, 2013 disclosure announcing a voluntary recall to remove the ForeCYTE Breast Health Test and the MASCT device from the market after receiving a warning letter from the FDA, the value of Atossa shares declined significantly.
If you have suffered a net loss ifrom investment in Atossa Genetics, Inc. securities purchased on or after November 8, 2012, and held through any of the revelations of negative information on February 25, 2013 and/or October 4, 2013, as described below, at no cost to you, contact us at 1-877-772-3975 or email at contact @ tripplevy
I just received the preliminary proxy that was filed by the law firm....the proxy details really interesting information regarding the process and shareholders' rights...if you want a copy here is law firm number to call 1-877-772-3975
i agree....big premium to yesterday but below what stock was less than 2 years ago....company was obviously poised to do much better and they saw that...stock should be worth around $40 in my opinion.